# Berry Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/berry-oncology

- Industry: Biotechnology
- Headquarters: Fuzhou, China
- Website: www.berryoncology.com
- Total disclosed funding: $99M
- Latest round: Series B (Jul 4, 2021)
- Investors on record: 10

## About

Established in 2017 and based in Fuzhou, China, Berry Oncology is a company that engages in the tumor genetic testing. It is a subsidiary of Berry Genomics Co., Ltd. In 2017, Berry Oncology has received investment from investment institutions such as Legend Capital, Boyu Capital, Qiming Venture Capital, and Terra Magnum Capital Partners. In 2018, the company and the National Liver Cancer Science Center jointly initiated a national multi-center prospective liver cancer very early warning screening project.

The company's products include tumor genetic susceptibility analysis, early screening, targeted and immune drug testing, efficacy monitoring, prognostic judgment, etc. In the field of early tumor screening and diagnosis, the company has launched a clinical research project for early screening and early diagnosis of tumors including liver cancer and lung cancer.

## Funding rounds

- Series B, Jul 4, 2021, $99M — Legend Capital, Qiming Venture Partners, China International Capital Corporation, China Merchants Capital, Xiamen C&D Group, Fujian Venture, Kaili Yifang Capital Management, Chenyou Capital
- Series A, Nov 8, 2017 — Legend Capital, Qiming Venture Partners, Boyu Capital, Terra Magnum Capital Partners

## Investors

- Legend Capital — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B
- Xiamen C&D Group — Series B
- Fujian Venture (https://capitalatlas.ai/funds/fujian-venture) — Series B
- Kaili Yifang Capital Management (https://capitalatlas.ai/funds/kaili-yifang-capital-management) — Series B
- Chenyou Capital — Series B